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Conjugated linoleic acid (CLA), a fatty acid found in ruminant food products, has been 
associated with anticarcinogenic activity. However, its effect on cancer metabolism is unclear. In 
this paper we evaluated the effects of cis-9, trans-11 CLA on the metabolic profile of MCF-7 and 
MDA-MB-231 breast cancer cells using high-resolution magic angle spinning (HR-MAS) nuclear 
magnetic resonance (NMR) spectroscopy. The NMR spectra showed that phosphocholine level, 
a cancer malignance biomarker, was reduced in both cells treated with CLA, but the reduction 
was more pronounced in MCF-7 cells. The NMR spectra also showed that CLA has opposite 
effect on MCF-7 and MDA-MB-231 acetone metabolism. Acetone signal has been observed in 
the spectra of MDA-MB-231 control cells, but not in the spectra of the cells treated with 50 and 
100 µM CLA. Conversely, the acetone signal is very small or not observed in the NMR spectra 
of MCF-7 control cells and in cells treated with 50 µM of CLA, but is very strong in the spectra 
of the cells treated with 100 µM of CLA. Therefore, this CLA concentration is causing a ketosis 
in MCF-7 cells by inducing the use of fatty acids as an energy source or by reducing acetone 
catabolism. These results indicate that CLA interfere in the metabolism of both cells. However, 
the strongest effect has been observed on the metabolism of MCF-7 cells cultivated in the presence 
of 100 µM CLA. Therefore, CLA could be a potential anticarcinogenic drug, especially for cells 
with positive estrogen receptor, such as MCF-7.
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Introduction
Conjugated linoleic acid (CLA) is a class of fatty acids 
that are typically found in meat and dairy products from 
ruminants (cattle, goats, and sheep).1 It has gained special 
attention because of its potential human health benefits, 
which include an anticarcinogenic activity.2 CLA is a group 
of positional and geometric isomers of linoleic acid (cis-9, 
cis-12 octadecadienoic acid). There are many CLA isomers, 
but cis-9, trans-11 represents 75-90% of the total CLA in 
ruminant fat.3 CLA is classified by the United States Food 
and Drug Administration (FDA) agency to be generally 
recognized as safe (GRAS) as disclosed in notice number 
GRN 000232.4
Most studies on the anticarcinogenic activity of CLA 
rely upon gene regulation (p53,p21 WAF1/CIP1, bax, 
and bcl-Xs).5-7 Recent studies have shown that CLA 
interferes on the expression of major oncogenes involved 
in programmed cell death (apoptosis)3,5 or on the regulation 
of protein kinase C isoforms in benign and malignant cells.8
In this work, the anticarcinogenic effects of cis-9, 
trans-11 CLA in intact breast cancer (BC) cells metabolism 
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were investigated using high-resolution magic angle 
spinning (1H HR-MAS) nuclear magnetic resonance 
(NMR) technique. HR-MAS NMR spectroscopy has been 
successfully used to study the metabolic profile of intact 
ex situ tissues from different types of cancer,9 especially 
BC.10 BC is the most common cancer and the one that has 
the highest incidence and mortality among all malignancies 
in women.11,12
The first study on the metabolic profile of BC tissue 
using HR-MAS was performed in 1998 by Cheng et al.13 
Since then, several HR-MAS studies have been performed 
in BC tissues in order to correlate NMR data with clinical 
observations as well as to differentiate tumor subclasses, 
to mention a few.14,15 Recently, Haukaas et al.10 reviewed 
the application of HR-MAS in BC and corroborated 
the potential of such technique in providing important 




MCF-7 and MDA-MB-231 BC cells are positive and 
negative estrogen receptors, respectively. The cells were 
cultivated in 75 cm2 cell culture flasks, in a CO2 incubator 
at 37 °C. MDA-MB-231 and MCF-7 cells were maintained 
in L-15 (Leibovitz, Cultilab) and DMEM (Dulbecco’s 
modified Eagle’s medium, Cultilab), respectively, both 
supplemented with 10% fetal bovine serum (FBS). Cell 
viability was tested by Trypan Blue exclusion before 
experiments.
Exposition of MDA-MB-231 and MCF-7 cells to CLA
To prepare the CLA supplemented media, we made a 
stock solution of CLA (1 mM) in FBS. This solution was 
sterile filtered using 0.22 µm syringe filters and diluted 
into the culture media DMEM and L-15 to obtain these 
supplemented media with 50 and 100 µM of CLA.16-19 
Before experiments, culture media were supplemented with 
10% of FBS. Each cell strain, MDA-MB-231 and MCF-7, 
were cultivated in three different 75 cm2 culture flasks. Cells 
were seeded in a density of ca. 1.4 × 104 cells mL-1, and 
after three days at 37 °C in 5% CO2, the culture medium 
of flasks was replaced by the CLA supplemented media in 
different concentrations (0, 50 and 100 µM of CLA). After 
three days of exposition to CLA, the cells were detached 
with trypsin, centrifuged, resuspended in deuterated water 
and re-centrifuged. The pellets of cells were submitted to 
NMR analysis. This procedure was applied to the three 
different experimental media in MDA-MB-231 and MCF-
7 cells, and four replicates of each concentration of CLA 
were performed to investigate the effect of this substance 
in tumor cells.
1H HR-MAS NMR analysis
1H HR-MAS NMR spectroscopy was performed at 
9.4 T (400.21 MHz for 1H) and 14.1 T (600 MHz for 
1H) on a DRX 400 Bruker NMR spectrometer and an 
Avance 600 Bruker NMR spectrometer, respectively. A 
spinning rate of 5 kHz was used. Sodium trimethylsilyl-
[2,2,3,3-2H4]-1-propionate (TMSP) was used as internal 
standard. The spectra were acquired with presaturation 
pulse of 1.5 s, acquisition time of 4.63 s (32K points), 
recycle delay of 4 s, and accumulation of 256 transients. 
In addition, a Carr-Purcell-Meiboom-Gill (CPMG) 
spin-echo train was used before acquisition by applying 
120 cycles separated by 1.2 ms of echo time. The free 
induction decay (FID) signal was multiplied by a 1.0-Hz 
(0.0025 ppm) line-broadening factor as well as a zero filled 
two-fold for Fourier transform. The Advanced Chemistry 
Development (ACD) Labs software was used for automatic 
phase adjustment and baseline correction. Samples were also 
analyzed using two-dimensional (2D) NMR spectroscopy 
methods, including COSY (correlation spectroscopy), 
1H,13C-HSQC (proton-carbon heteronuclear single-quantum 
correlation spectroscopy), and 1H,13C-HMBC (proton-carbon 
heteronuclear multiple bond correlation spectroscopy). 
Online databases (e.g., Human Metabolome Database 
(HMDB) and Chenomx) were also suitable for assignments. 
One-dimensional (1D) 1H HR-MAS spectra were normalized 
by correcting baseline offset to zero as well as dividing each 
data point by the sum of all data points. The values were then 
multiplied by 1000.
Results
Figures 1 and 2 show the typical 1H HR-MAS NMR 
spectra of MDA-MB-231 and MCF-7 BC cells, respectively. 
These spectra were acquired using CPMG pulse sequence 
in order to suppress the broad signals of macromolecules 
and molecular assemblies as well as to highlight the sharp 
signals of the metabolites.10 Figures 1a and 2a present the 
spectra of CLA-untreated cells (control). Figures 1b and 2b 
show the spectra of cells treated with 50 µM of CLA, while 
Figures 1c and 2c display the spectra of those treated with 
100 µM of CLA. Although the chemical shift (d, in ppm) 
profiles assigned to the metabolites in MDA-MB-231 and 
MCF-7 cells were similar, the peak areas were different, 
revealing differences in their concentrations in cells.
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The spectra of MCF-7 and MDA-MB-231 cells have 
been previously assigned elsewhere using 1D NMR 
database and 2D NMR experiments.20,21 The major 
components of these cells were lactate quartet at d 4.11 
and doublet at d 1.32, threonine at d 1.33, alanine at d 1.47, 
acetate singlet at d 1.91, acetone singlet at d 2.2, choline 
at d 3.20, phosphocholine at d 3.22, taurine at d 3.25 and 
3.42, and guanidinoacetate at d 3.78.
The non-overlapped peak of each metabolite was used 
to calculate its relative intensity (in triplicate) in relation to 
the total area of each normalized spectrum. The intensities 
of some signals were significantly different in both control 
BC cell lines. The levels of threonine (2.06 ± 0.1), alanine 
(0.30 ± 0.04), acetate (0.26 ± 0.02), creatine (0.45 ± 0.09), 
and taurine (0.77 ± 0.10) were found to be higher in control 
MCF-7 cells (Figure 2a). On the other hand, acetone 
(1.56 ± 1.05), choline (1.11 ± 0.30), and phosphocholine 
(11.22 ± 1.30) contents were high in control MDA-MB-231 
cells (Figure 1a). Lactate content was similar in both cells 
(1.67 ± 0.30 and 1.69 ± 0.40 in MCF-7 and MDA-MB-231 
control cells, respectively). The differences observed 
between the metabolic profiles of non-tumor cells and 
those of MCF-7 and MDA-MB-231 have been addressed 
previously.22
The main difference observed in MDA-MB-231 cells 
treated with 100 µM of CLA was the reduction of the peak 
assigned to phosphocholine (d 3.23 ppm) by 33.5 ± 12.5% 
(Figure 1c) when compared to control cells (Figure 1a). 
Similarly, the intensity of phosphocholine in MCF-7 
cells decreased by 32.5 ± 19.1% after treatment with 
100 µM of CLA (Figure 2c) when compared to control 
cells (Figure 2a).
Additionally, we observed a difference in the intensity 
of the signal assigned to acetone, which were in low 
concentration in MDA-MB-231 control cells (Figure 1a) 
and were not observed after treatments with 50 and 
100 µM of CLA (Figures 1b and 1c, respectively). The 
NMR spectra of MCF-7 control and treated cells (50 µM 
of CLA) showed very small acetone signal (Figures 2a and 
2b). Conversely, the spectra of cells treated with 100 µM of 
CLA shows a strong acetone signal (Figure 2c), more than 
an order of magnitude increases when compared to control 
MCF-7 cells. The intensities of the other metabolites did 
not change significantly when MCF-7 and MDA-MB-231 
cells were exposed to 100 µM of CLA (Figures 1c and 2c).
Discussion
The reduction of the level of phosphocholine, biomarker 
of malignance, when both MCF-7 and MDA-MB-231 BC 
cells were treated with 100 µM of CLA, demonstrates 
the influence of this fatty acid on the metabolism of 
membrane compounds that play a crucial role in cancer 
cell growth. The reduction in phosphocholine level was 
more pronounced in MCF-7 cells indicating that these cells 
might be more susceptible to CLA.
Reduced phosphocholine levels were also observed 
in these BC cells upon treatment with commercial 
chemotherapy drugs, such as tamoxifen, cisplatin, and 
doxorubicin.20,21 However, CLA showed minor influence 
on other metabolites when contrasted with commercial 
drugs, indicating that CLA may cause fewer side effects 
even when used at much higher concentrations.
CLA also affects the acetone metabolism in both BC 
cells, but in opposite direction. It reduces the concentration 
of acetone in MDA-MB-231 cells to an undetected level. As 
Figure 1. 1H HR-MAS NMR spectra of MDA-MB-231 breast cancer cells. 
(a) Control cells; (b) cells treated with 50 µM or (c) 100 µM of CLA. 
1H HR-MAS NMR spectra were acquired using CPMG as T2-filtered to 
remove signals of large molecules with short transverse relaxation times. 
The arrow indicates the acetone signal in breast cancer cells.
Figure 2. 1H HR-MAS NMR spectra of MCF-7 breast cancer cells. (a) 
Control cells; (b) cells treated with 50 µM or (c) 100 µM of CLA. 1H HR-
MAS NMR spectra were acquired using CPMG as T2-filtered to remove 
signals of large molecules with short transverse relaxation times. The 
arrow indicates the acetone signal in breast cancer cells.
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this cell line is more invasive than MCF-7 cells, this might 
indicate that CLA is reducing the MDA-MB-231 activity 
and the cells are not using fatty acid as energy source, 
reducing acetone biosynthesis, even in absence of glucose.
Conversely, when the MCF-7 cells were treated with 
100 µM of CLA they present large amount of acetone 
indicating an increase of acetone synthesis or reduction 
in acetone catabolism, causing ketosis. Ketosis is a 
process that normally happens in glucose-depleted cells 
that have to use other energy source such as fatty acids.23 
Consequently, the use of fatty acid as energy source 
can reduce the proliferation and death of cells.23 This 
hypothesis agrees with O’Shea et al.23 that associated the 
cytotoxic effect of CLA on MCF-7 cells to the extensive 
lipid peroxidation.
Another hypothesis for the high acetone content in 
MCF-7 cells treated with 100 µM of CLA could be related 
to the degradation of acetone by the cytochrome P450 
(CYP), especially isoenzyme CYP2E1.24 This enzyme is 
involved in the degradation of small molecules, including 
acetone, and have been linked with inflammatory reaction 
and carcinogenesis in different tissues, suggesting that 
CYP2E1 may be involved in tumor growth.24,25
Clinical studies indicate the existence of a higher 
expression of CYP2E1 in breast cancer compared to normal 
tissue, and that activity of this isoenzyme is in agreement 
with the substrate (small molecules) metabolized.24 It was 
also reported that CYP2E1 is expressed in liver, but also 
in other tissues such as breast tissue.25 It was performed 
an ectopic expression of CYP2E1 in breast cancer cells 
with different substrates, including ethanol, indicating that 
CYP2E1 plays a pivotal role in mammary carcinogenesis.25 
However, the acetone metabolism by CYP2E1 in breast 
cancer cells has not been reported in literature earlier.
Therefore, the acetone signal can be associated to fatty 
acids β-oxidation process or to the reduction of CYP2E1 
expression or simultaneous to both processes, indicating 
potential CLA anticarcinogenic mechanisms in MCF-7 
cells.
Conclusions
The results corroborate that 1H HR-MAS NMR 
spectroscopy is an important tool to analyze and 
discriminate the metabolic profiles of intact cancer cells 
treated with “potential anticarcinogenic” compounds 
such as CLA. The NMR spectra demonstrated that CLA 
is a potential anticarcinogenic compound, evidenced 
by the significant reduction on phosphocholine level, a 
malignance biomarker. The NMR spectra also were able 
to show that CLA affects the acetone metabolism, reducing 
its concentration in MDA-MB-231 cells and increasing its 
concentration in MCF-7 cells treated with 100 µM CLA. 
These NMR results indicate that the strongest CLA 
effect was observed on the metabolism of MCF-7 cells 
cultivated in the presence of 100 µM CLA. Therefore, CLA 
could be a potential anticarcinogenic compound, especially 
for BC cells with positive estrogen receptor, such as MCF-7.
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